No Data
No Data
Founder Securities: Traditional Chinese medicine sector H1 performance is under short-term pressure. The performance of branded OTC companies is better than the industry as a whole.
Due to the impact of high base in the same period of 23Q2 and external factors such as centralized procurement and same-price policy, the performance of the traditional Chinese medicine sector in Q2 is under pressure compared to the same period last year, and it also declined compared to Q1.
Yunnan Baiyao: 2024 Semi-Annual Report (English version)
Results: Yunnan Baiyao Group Co.,Ltd Beat Earnings Expectations And Analysts Now Have New Forecasts
Yunnan Baiyao Group's H1 Profit Up 13%, Operating Income Inches Up
Yunnan Baiyao: 2024 Semi-Annual Report
Yunnan Baiyao: Summary of the 2024 Semi-Annual Report
No Data
No Data